News Releases

Month Year

Month Year

Nov 24, 2020

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 13, 2020

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Nov 6, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2020

Insmed to Present at Two November Conferences
Oct 29, 2020

Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--
Oct 28, 2020

European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options

-- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
Oct 20, 2020

Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020
Oct 2, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 30, 2020

Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
Sep 16, 2020

Insmed to Host R&D Day on September 30, 2020

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation